Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
|
|
Oncocyte Corp (OCX)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/12/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/10/2023 |
8-K/A
| Quarterly results |
| 10/05/2023 |
8-K
| Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits Interactive Data |
| 08/17/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 08/10/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/10/2023 |
8-K
| Quarterly results |
| 07/24/2023 |
8-K
| Quarterly results |
| 07/21/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 07/14/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...|
Docs:
|
"AMENDMENT TO AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AMENDMENT , is entered into effective July 13, 2023 by and between Oncocyte Corporation , a California corporation located at 15 Cushing, Irvine, California 92618 and Joshua Riggs . WHEREAS, the Company and Executive previously entered into that certain Amended and Restated Employment Agreement, effective May 1, 2023 ; WHEREAS, pursuant to Section 12 of the Employment Agreement, the Employment Agreement may be amended, in writing, signed by both the Company and Executive; WHEREAS, the Company and Executive desire to amend the Employment Agreement as set forth herein; and WHEREAS, capitalized terms not otherwise defined in this Amendment shall have the meanings ascribed to such terms in the Employment Agreement. NOW, THEREFORE, in ..." |
|
| 07/10/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 07/03/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/30/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 06/29/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 06/15/2023 |
4
| KINGSLEY ALFRED D (Director) has filed a Form 4 on Oncocyte Corp|
Txns:
| Bought 30,000 shares
@ $0.2149, valued at
$6.4k
|
|
| 06/08/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 06/06/2023 |
8-K
| Investor presentation |
| 05/19/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 05/11/2023 |
8-K
| Quarterly results |
| 05/01/2023 |
10-K/A
| Annual Report for the period ended December 31, 2022 [amend] |
| 04/18/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/18/2023 |
4/A
| Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] |
| 04/14/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 04/13/2023 |
8-K
| Quarterly results |
| 04/05/2023 |
4
| BROADWOOD PARTNERS, L.P. (10% Owner) has filed a Form 4 on Oncocyte Corp|
Txns:
| Bought 26,827,638 shares
@ $0.3017, valued at
$8.1M
|
|
| 04/05/2023 |
4
| Gutfreund John Peter (Director) has filed a Form 4 on Oncocyte Corp|
Txns:
| Granted 705,000 shares
@ $0.3544, valued at
$249.9k
Granted 1,000,000 shares
@ $0.3544, valued at
$354.4k
Disposed/sold 588 convertible preferred
@ $0 |
|
| 04/05/2023 |
4
| Arno Andrew (Director) has filed a Form 4 on Oncocyte Corp|
Txns:
| Granted 141,084 shares
@ $0.3544, valued at
$50k
Granted 141,084 shares
@ $0.3544, valued at
$50k
Granted 141,084 shares
@ $0.3544, valued at
$50k
|
|
| 04/05/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 04/05/2023 |
8-K
| Results of Operations and Financial Condition, Other Events Interactive Data |
| 03/31/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 03/08/2023 |
4
| PURA VIDA INVESTMENTS, LLC (10% Owner) has filed a Form 4 on Oncocyte Corp|
Txns:
| Disposed of 3,890,111 shares
@ $0 |
|
| 03/02/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 02/28/2023 |
4
| Riggs Josh (CEO) has filed a Form 4 on Oncocyte Corp|
Txns:
| Granted 116,426 options to buy
@ $0.39, valued at
$45.4k
|
|
| 02/28/2023 |
4
| John Anish M. (CFO) has filed a Form 4 on Oncocyte Corp|
Txns:
| Granted 121,381 options to buy
@ $0.39, valued at
$47.3k
|
|
| 02/23/2023 |
8-K
| Asset disposition|
Docs:
|
"Second AMENDMENT TO STOCK PURCHASE AGREEMENT THIS SECOND AMENDMENT TO STOCK PURCHASE AGREEMENT is adopted as of the 16th day of February, 2023 , by and among Oncocyte Corporation, a California corporation , Dragon Scientific, LLC, a Delaware limited liability company , and Razor Genomics, Inc., a Delaware corporation . Seller, Company, and Buyer are referred to herein individually as a “Party” and collectively as the “Parties.” Capitalized terms used and not otherwise defined herein shall have the meanings ascribed to such terms in the Stock Purchase Agreement . WHEREAS, Buyer, Seller and the Company have entered into that certain Stock Purchase Agreement, dated as of December 15, 2022 and amended the same pursuant to that certain First Amendment to Stock Purchase Agreement entered into as...",
"ONCOCYTE CORPORATION UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL INFORMATION On February 16, 2023, Oncocyte Corporation completed its sale of 3,188,181 shares of common stock of its wholly-owned subsidiary Razor Genomics, Inc. , which constitutes approximately 70% of the issued and outstanding equity interests of Razor on a fully-diluted basis, pursuant to a previously announced Stock Purchase Agreement with Dragon Scientific, LLC, a Delaware limited liability company , and Razor, a Delaware corporation . In connection with the Closing, Oncocyte transferred to Razor all of the assets and liabilities related to DetermaRx TM , a test used to predict a patient’ s risk of cancer recurrence following surgery and response to chemotherapy in early-stage lung cancer. Following the Closing...",
"ONCOCYTE COMPLETES RAZOR GENOMICS TRANSACTION" |
|
|
|
|